Everything below concerns freeze-thaw. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
== Production == GnIH neurons reside primarily in the dorsomedial nucleus of the hypothalamus (humans and rodents) and the paraventricular nucleus of the hypothalamus (avian species). Some GnIH neuron terminals in both mammalian and avian species project to the median eminence. GnIH and GnRH (gonadotropin releasing hormone) neurons exist in close proximity in the hypothalamus, which may enable the direct inhibition of GnRH neurons by GnIH. GnIH enters the bloodstream via the hypothalamo-hypophyseal portal system, the vascular network supplying both the hypothalamus and the pituitary. GnIH and GnIH receptor (GnIH-R) mRNA is expressed in the hypothalamus, pituitary, and ovaries. GnIH expression is highest during proestrus and lowest during estrus, suggesting the estrus cycle influences release of the hormone. Furthermore, GnIH neuronal cell counts in multiple vertebrates fluctuate with an organism's parental status. GnIH cell count may also vary with breeding season in some species. For instance, European starlings (Sturnus vulgaris) with greater reproductive success exhibited higher quantities of GnIH-producing cells than did those that were less successful, but this effect did not appear until mid-breeding season.
=== Spokesman for social responsibility === After the Second World War, Hahn came out strongly against the use of nuclear energy for military purposes. He saw the application of his scientific discoveries to such ends as a misuse, or even a crime. The historian Lawrence Badash wrote: "His wartime recognition of the perversion of science for the construction of weapons, and his postwar activity in planning the direction of his country's scientific endeavours now inclined him increasingly toward being a spokesman for social responsibility."
== Efforts to characterize all human cell types == Several efforts have been made to make a list or a map of all human cells. One of the largest and most recent is the HuBMAP (Human BioMolecular Atlas Program). The HuBMAP project has organized 1551 different samples in 17 collections, each dedicated to a different system. However, this project still only mapped about 31 of the human body's 70 organs. Their datasets and visualisations place great emphasis on biomarkers and location in the body, but less on cell development and how cells can change over time. Usually specific surface proteins are used to identify cells, and based on this they are put into different categories. Another major effort to make an overview of these proteins that allows us to observe cell types is the Human Protein Atlas. A similar project, the Human Brain Project has also attempted to map the human brain, although much of the publicly accessible model does not have cellular resolution.
Sources: en.wikipedia.org
Here, a stock solution of glutamine is added in increasing increments with a high-accuracy instrument and diluted to the same volume in volumetric flasks. The result is 4 standard solutions with varying known concentrations (along with a blank for instrument calibration). The final concentration in each is calculated using the formula for molar concentration.
In all, over a million Canadians served in the armed forces during the Second World War. Canadian troops played important roles in many key battles of the war, including the failed 1942 Dieppe Raid, the Allied invasion of Italy, the Normandy landings, the Battle of Normandy, and the Battle of the Scheldt in 1944. Canada provided asylum for the Dutch monarchy while that country was occupied and is credited by the Netherlands for major contributions to its liberation from Nazi Germany.
=== Europe === The 2026 European drug report, published by the European Union Drugs Agency, found that in a one year period prior ot the report being published that approximately 8.7% of all people in Europe aged between 15 to 64 had used cannabis during this period. This figure of 8.7% of all people in Europe is equivalent to around 25 million people. The report also found that for people aged 15 to 34 there was around 15.4 million people or roughly 15.3% who had used cannabis during this same one year period prior to the report being published. As well as this, the report found that 18% of 15 to 24 year olds reported they had used cannabis recently with there being 13% of people aged 15 to 16 who reported having used cannabis at least once in their lifetime. During this same period there was nearly 4.5 million people who reported using cannabis daily or almost daily. The 2026 European drug report also found that an estimated 850,000 people or around 0.3% of the EU adult population used opioids in 2024 with there being 860 000 people using opioids in 2023. The same report also estimated that there were 505 000 people who received opioid agonist treatment for opioid drug addiction in EU Member States in 2024 with there being 511 000 people in 2023.
== Statistical methods == The data generated in metabolomics usually consist of measurements performed on subjects under various conditions. These measurements may be digitized spectra, or a list of metabolite features. In its simplest form, this generates a matrix with rows corresponding to subjects and columns corresponding with metabolite features (or vice versa). Several statistical programs are currently available for analysis of both NMR and mass spectrometry data. A great number of free software are already available for the analysis of metabolomics data shown in the table. Some statistical tools listed in the table were designed for NMR data analyses were also useful for MS data. For mass spectrometry data, software is available that identifies molecules that vary in subject groups on the basis of mass-over-charge value and sometimes retention time depending on the experimental design. Once metabolite data matrix is determined, unsupervised data reduction techniques (e.g. PCA) can be used to elucidate patterns and connections. In many studies, including those evaluating drug-toxicity and some disease models, the metabolites of interest are not known a priori. This makes unsupervised methods, those with no prior assumptions of class membership, a popular first choice. The most common of these methods includes principal component analysis (PCA) which can efficiently reduce the dimensions of a dataset to a few which explain the greatest variation.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
肽键在 214 nm 附近有较强吸收，适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。